TERT and melanoma: These TERT promoter mutations are currently the most common non-coding somatic mutations in cancer and are present in many types of cancers, including melanoma (67%), glioma (51.1%, specially 83.3% in primary glioblastoma, which is the most common and aggressive type of brain tumor), myxoid liposarcoma (79%), osteosarcoma (4.3%), hepatocellular carcinoma (44%), urothelial carcinoma (50.8%), squamous cell carcinoma (14.4%), medulloblastomas (21%), ovarian clear cell carcinoma (15.9%), thyroid cancer (10%), and bladder cancer (59%) [40,41,44,45,46].